Victory Capital Management Inc. Increases Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Victory Capital Management Inc. raised its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGNDFree Report) by 78.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,409 shares of the biotechnology company’s stock after acquiring an additional 7,652 shares during the quarter. Victory Capital Management Inc.’s holdings in Ligand Pharmaceuticals were worth $1,043,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of Ligand Pharmaceuticals by 95.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 441 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 215 shares during the last quarter. Lazard Asset Management LLC acquired a new position in shares of Ligand Pharmaceuticals during the second quarter valued at approximately $39,000. FMR LLC raised its holdings in shares of Ligand Pharmaceuticals by 38.0% during the first quarter. FMR LLC now owns 566 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 156 shares during the last quarter. State of Wyoming acquired a new stake in shares of Ligand Pharmaceuticals in the fourth quarter valued at approximately $45,000. Finally, C M Bidwell & Associates Ltd. increased its holdings in shares of Ligand Pharmaceuticals by 8,373.3% in the second quarter. C M Bidwell & Associates Ltd. now owns 1,271 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 1,256 shares during the last quarter. Institutional investors and hedge funds own 89.19% of the company’s stock.

Ligand Pharmaceuticals Stock Performance

NASDAQ:LGND opened at $75.64 on Tuesday. Ligand Pharmaceuticals Incorporated has a one year low of $49.24 and a one year high of $85.70. The stock has a market cap of $1.31 billion, a PE ratio of 111.24 and a beta of 1.01. The stock has a 50 day moving average price of $71.11 and a 200 day moving average price of $64.08.

Wall Street Analyst Weigh In

Separately, Benchmark reaffirmed a “buy” rating and issued a $95.00 price target on shares of Ligand Pharmaceuticals in a report on Wednesday, December 13th. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Ligand Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $116.33.

View Our Latest Research Report on LGND

Ligand Pharmaceuticals Profile

(Free Report)

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.

See Also

Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Incorporated (NASDAQ:LGNDFree Report).

Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.